Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Renin‐Angiotensin System Inhibitors in Patients With COVID‐19: A Meta‐Analysis of Randomized Controlled Trials Led by the International Society of Hypertension
Sonali R. Gnanenthiran, Claudio Borghi, Dylan Burger, et al.
Journal of the American Heart Association (2022) Vol. 11, Iss. 17
Open Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association
Seth S. Martin, Aaron W. Aday, Zaid Almarzooq, et al.
Circulation (2024) Vol. 149, Iss. 8
Open Access | Times Cited: 934
Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support–Free Days in Patients Hospitalized With COVID-19
Simin Aysel Florescu, Dragos Stanciu, Mihaela Zaharia, et al.
JAMA (2023) Vol. 329, Iss. 14, pp. 1183-1183
Open Access | Times Cited: 49
Risk factors for acute kidney injury in COVID-19 patients: an updated systematic review and meta-analysis
Jialing Zhang, Qi Pang, Ting Zhou, et al.
Renal Failure (2023) Vol. 45, Iss. 1
Open Access | Times Cited: 27
COVID-19 and metabolic syndrome
Harsha Dissanayake
Best Practice & Research Clinical Endocrinology & Metabolism (2023) Vol. 37, Iss. 4, pp. 101753-101753
Open Access | Times Cited: 19
Hypertension management before and under the COVID-19 pandemic: lessons and future directions
Yoichi Nozato, Kōichi Yamamoto, Hiromi Rakugi
Hypertension Research (2023) Vol. 46, Iss. 6, pp. 1471-1477
Open Access | Times Cited: 18
Atherosclerosis, Cardiovascular Disease, and COVID-19: A Narrative Review
Carles Vilaplana-Carnerero, Maria Giner‐Soriano, Ángela Domı́nguez, et al.
Biomedicines (2023) Vol. 11, Iss. 4, pp. 1206-1206
Open Access | Times Cited: 18
A Review of Heart Failure in Patients with COVID-19
Hanad Bashir, Mehmet Yıldız, John Cafardi, et al.
Heart Failure Clinics (2023) Vol. 19, Iss. 2, pp. e1-e8
Open Access | Times Cited: 11
Beyond the Guidelines: Original Research on Real-World Outcomes of Anticoagulation and Corticosteroid in COVID-19
Alison Leslie, Scott A. Chapman, Katelyn Tessier, et al.
International Journal of Infectious Diseases (2025), pp. 107834-107834
Open Access
Modulation of the Renin-Angiotensin System against COVID-19: A path forward?
Serge Camelo, Waly Dioh, J. Pedro Teixeira, et al.
International Journal of Infectious Diseases (2025), pp. 107867-107867
Open Access
Reducing Oxygen Demand to Alleviate Acute Kidney Injury
Xiaoming Zhou
Frontiers in Bioscience-Landmark (2023) Vol. 28, Iss. 3
Open Access | Times Cited: 9
Overreactive macrophages in SARS-CoV-2 infection: The effects of ACEI
Dominik Felkle, Katarzyna Zięba, Konrad Kaleta, et al.
International Immunopharmacology (2023) Vol. 124, pp. 110858-110858
Open Access | Times Cited: 9
Effects of Losartan on Patients Hospitalized for Acute Coronavirus Disease 2019: A Randomized Controlled Trial
Karen Tran, Pierre Asfar, Matthew P. Cheng, et al.
Clinical Infectious Diseases (2024) Vol. 79, Iss. 3, pp. 615-625
Closed Access | Times Cited: 3
Oxygen Therapy in Pulmonary Vascular Disease
Manuel Schuster, Julian Müller, Esther I. Schwarz, et al.
Heart Failure Clinics (2023) Vol. 19, Iss. 1, pp. e1-e11
Open Access | Times Cited: 8
Nirmatrelvir/ritonavir for patients with SARS-CoV-2 infection and impaired kidney function during the Omicron surge
Jiayi Yan, Hong Cai, Jieying Wang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 8
Interaction of COVID-19 With Common Cardiovascular Disorders
Peter K. Boulos, Scott Freeman, Timothy D. Henry, et al.
Circulation Research (2023) Vol. 132, Iss. 10, pp. 1259-1271
Open Access | Times Cited: 7
Effects of renin–angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials
Matthew M.Y. Lee, Toru Kondo, Ross T. Campbell, et al.
European Heart Journal - Cardiovascular Pharmacotherapy (2023) Vol. 10, Iss. 1, pp. 68-80
Open Access | Times Cited: 6
Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in hospitalized patients with COVID-19: an updated systematic review and meta-analysis of randomized clinical trials
Joseph Alexander Paguio, Bruce Adrian Casipit, Tara A John, et al.
Expert Review of Cardiovascular Therapy (2023) Vol. 21, Iss. 3, pp. 219-226
Closed Access | Times Cited: 5
Relationship between the structure, function and endothelial damage, and vascular ageing and the biopsychological situation in adults diagnosed with persistent COVID (BioICOPER study). A research protocol of a cross-sectional study
Leticia Gómez‐Sánchez, Olaya Tamayo‐Morales, Nuria Suárez-Moreno, et al.
Frontiers in Physiology (2023) Vol. 14
Open Access | Times Cited: 5
Predicting acute kidney injury onset using a random forest algorithm using electronic medical records of COVID-19 patients: the CRACoV-AKI model
Katarzyna Krzanowska, Krzysztof Batko, Karolina Niezabitowska, et al.
Polskie Archiwum Medycyny Wewnętrznej (2024)
Open Access | Times Cited: 1
Impact of prior antihypertensive treatment on COVID-19 outcomes, by active ingredient
Rosa María García-Álvarez, Maruxa Zapata‐Cachafeiro, Irene Visos‐Varela, et al.
Inflammopharmacology (2024) Vol. 32, Iss. 3, pp. 1805-1815
Open Access | Times Cited: 1
Acromegaly and COVID-19, lessons, and new opportunities
Elena V. Varlamov, Maria Fleseriu
Pituitary (2024) Vol. 27, Iss. 6, pp. 935-944
Closed Access | Times Cited: 1
Role of angiotensin converting enzyme in pathogenesis associated with immunity in cardiovascular diseases
Xinyi Li, Hua‐Sheng Ding, Gaoke Feng, et al.
Life Sciences (2024) Vol. 352, pp. 122903-122903
Closed Access | Times Cited: 1
Association between renin‐angiotensin antagonism and COVID‐19–related mortality in patients with essential hypertension: A single center, retrospective cohort study
Vijayvardhan Kamalumpundi, Shuntaro Kawasaki, Linhai Cheng, et al.
Journal of Clinical Hypertension (2024) Vol. 26, Iss. 9, pp. 1039-1044
Open Access | Times Cited: 1
Timing matters in the use of renin-angiotensin system modulators and COVID-related cognitive and cerebrovascular dysfunction
Mackenzi Meier, Sara J. Becker, Erica Levine, et al.
PLoS ONE (2024) Vol. 19, Iss. 7, pp. e0304135-e0304135
Open Access | Times Cited: 1
Evolution of Cardiovascular Risk Factors in Post-COVID Patients
Irina Mihaela Abdulan, Veronica Feller, Andra Oancea, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 20, pp. 6538-6538
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top